{
  "id": 733614,
  "title": "Celltrion Secures FDA Fast Track Designation for All Three Clinical-Stage ADC Candidates",
  "url": "https://urgent.news/2026/08/13/celltrion-secures-fda-fast-track-designation-for-all-three-clinical",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-13T05:26:52.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=156069"
  },
  "original_language": "en",
  "account": "Celltrion announced on August 13 that its three clinical-stage antibody-drug conjugate (ADC) candidates have received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation includes CT-P73, CT-P70, and CT-P71, all currently in Phase 1 clinical development. CT-P73 targets Tissue Factor in cervical cancer, while CT-P70 and CT-P71 target c-MET and Nectin-4, respectively. Fast Track designation allows for more frequent communication between developers and the FDA, as well as potential eligibility for Rolling Review and Accelerated Approval. Celltrion plans to evaluate clinical data and determine the best commercialization strategy for each candidate, whether that means direct development and sales or licensing agreements with global pharmaceutical companies. The company believes this approach will maximize long-term value and opportunities for earlier monetization.",
  "summary": "Celltrion has secured FDA Fast Track designation for all three of its clinical-stage antibody-drug conjugate (ADC) candidates, including CT-P73, CT-P70, and CT-P71. The FDA's Fast Track program aims to expedite the development and review of therapies for serious conditions with significant unmet medical needs. The three ADC candidates target c-MET, Nectin-4, and Tissue Factor, respectively, and are currently in Phase 1 clinical development. By receiving Fast Track status for its entire clinical-stage ADC portfolio, Celltrion gains regulatory advantages and increased flexibility in determining the commercialization strategy for each candidate. For the most advanced candidate, CT-P73, which targets Tissue Factor overexpressed in cervical cancer and other solid tumors, preclinical studies have shown that it demonstrates antitumor activity comparable or superior to existing Tissue Factor-targeting therapy, while also presenting an improved safety profile.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}